82960
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 17
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.952402043
- umap2_2d
- 0.045331773
- umap1_3d
- 0.126685668
- umap2_3d
- 3.102752587
- umap3_3d
- -0.602400256
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.390
- DNA_REPAIR+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- OXIDATIVE_PHOSPHORYLATION+0.210
- E2F_TARGETS+0.190
- MYC_TARGETS_V1+0.170
- PI3K_AKT_MTOR_SIGNALING+0.170
- WNT_BETA_CATENIN_SIGNALING+0.160
- BILE_ACID_METABOLISM+0.120
- PEROXISOME+0.110
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.370
- HYPOXIA-0.340
- ANGIOGENESIS-0.300
- HEDGEHOG_SIGNALING-0.260
- ANDROGEN_RESPONSE-0.230
- TNFA_SIGNALING_VIA_NFKB-0.220
- COAGULATION-0.190
- ESTROGEN_RESPONSE_LATE-0.180
- GLYCOLYSIS-0.180
- COMPLEMENT-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0717 | Med | Medulloblastoma | 0.799 |
| 2 | MNG903 | — | — | 0.776 |
| 3 | MNG951 | — | — | 0.775 |
| 4 | BS_53M8PP88 | Ependymoma NOS | — | 0.759 |
| 5 | R4 | — | — | 0.755 |
| 6 | R28 | — | — | 0.755 |
| 7 | MNG986 | — | — | 0.743 |
| 8 | MDT-AP-1199 | Med | Medulloblastoma | 0.743 |
| 9 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.737 |
| 10 | MDT-AP-0417 | Med | Medulloblastoma | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |